Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

THE WOODLANDS, Texas, Dec. 14, 2010 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced top-line results from a recently completed Phase 2a study of LX2931 in patients with rheumatoid arthritis (RA).  LX2931 is an orally-delivered, small molecule drug candidate that inhibits sphingosine-1-phosphate (S1P) lyase, an enzyme important for modulating the immune system by controlling S1P levels in lymphoid tissues. The trial was the first test of this new anti-inflammatory mechanism of action in patients and was designed to obtain safety and tolerability information and signals of efficacy.  

Results from the 12-week, randomized, double-blind, placebo-controlled study in 208 patients with RA demonstrated that all three doses tested, 70 mg, 110 mg, and 150 mg given once per day, were well tolerated over the 12-week treatment period.  Taken together, the data also suggested that patients treated with 150 mg once daily of LX2931 showed an improvement in the primary efficacy endpoint, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12 (60% versus 49% for placebo).  Patients treated with 70 mg or 110 mg once daily did not indicate improvement in the ACR20 at week 12 (44% and 41% response rates, respectively) relative to placebo. Adverse events for all three LX2931 dose groups were predominantly mild-to-moderate, with frequencies similar to the placebo group.

"We believe the preliminary signal of efficacy and the favorable safety profile observed in this trial supports further study
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... -- Anpac Bio-Medical Science Co., Ltd., Chief Executive Officer and ... research team are introducing what the 2015 Nobel Prize ... "game changing" and "breakthrough" early cancer detection technology research ... Annual Meeting in Chicago, Illinois , ... An accomplished inventor with over 200 patent applications (100 ...
(Date:5/29/2015)... , May 29, 2015 Actinobac Biomed, ... originally funded with investments from Foundation Venture Capital Group ... Bio International 2015 as part of the Start-Up Stadium ... FVCG President James M. Golubieski . ... biotechnology industry, will be held in Philadelphia ...
(Date:5/29/2015)... 28, 2015 Research and Markets ( ... PharmaBiotech,s new report "Cardiovascular Drug Delivery - ... Drug delivery to the cardiovascular system ... of the anatomy and physiology of the vascular ... organs of the body. Drugs can be introduced ...
Breaking Medicine Technology:Anpac Bio-Medical Introduces 'Game Changing' Cancer Screening Tech at American Society of Clinical Oncology Meeting - Chicago 5/29 - 6/2 2Anpac Bio-Medical Introduces 'Game Changing' Cancer Screening Tech at American Society of Clinical Oncology Meeting - Chicago 5/29 - 6/2 3Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 2Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 3Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 3
... (NYSE Amex: CXM ) today announced that ... shares of its common stock in a registered direct ... deducting placement agent,s fees and estimated offering expenses. The ... purchased the shares at a price of $0.28 per ...
... Mass., Feb. 16, 2012  Idenix Pharmaceuticals, Inc. (NASDAQ: ... results for the fourth quarter and year end 2011 on ... Idenix management will host a conference call at ... the company,s financial results for the fourth quarter and year ...
Cached Medicine Technology:Cardium Announces Closing of $5.0 Million Equity Financing 2Cardium Announces Closing of $5.0 Million Equity Financing 3
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 According to ... one in 10 full-time workers has a substance abuse problem ... from more than 111,500 adults with full-time jobs, revealed that ... in the previous year. (1) The National Council on Alcoholism ... billion per year, and an estimated 70% of the 14.8 ...
(Date:5/29/2015)... 2015 To compile the list, the ... that have several awards for clinical and general excellence. ... stood out to them in terms of overall excellence, ... , The 50 Great Health Systems to Know 2015 ... (Altamonte Springs, Fla.) , Advocate Health Care (Downers Grove, ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 World Patent ... products, announces that it has signed a 10 year ... patent that aims to let people learn about any ... real time. , "This is an exciting day for ... said Scott J. Cooper, CEO and Creative Director of ...
(Date:5/29/2015)... Mediaplanet has joined forces with Raw Elements ... importance of proper sun protection. The print component of ... circulation of approximately 250,000 copies and an estimated readership ... through a vast social media strategy, and across a ... explore the digital version of the campaign, click ...
(Date:5/29/2015)... BC (PRWEB) May 29, 2015 Shaila ... & Sports Rehab, has recently stated in a new ... and suffer”. Urinary Continence is commonly seen as a ... before seeking help. Expert physiotherapists like Shaila Jiwa try ... the condition. , Incontinence is a condition that ...
Breaking Medicine News(10 mins):Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 3Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 4Health News:Becker's Hospital Review Names 50 Great Health Systems to Know 2Health News:Becker's Hospital Review Names 50 Great Health Systems to Know 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5Health News:Patients of Urinary Incontinence Should Not "Hide And Suffer," States Physiotherapist from Burnaby Physiotherapy Clinic 2
... have allegedly found inconsistencies in President Bush's AIDS-fighting program//, ... difficult, to gauge the success of the programme. ... AIDS program, valued at $15-billion has not enabled a ... has assisted. The Bush administration is now trying to ...
... of dioxin in a U.S. beef consignment to Seoul, according ... and the American beef industry are still unconvinced about the ... which is higher than Korea’s 5-picogram level. ,USDA ... we found 6.26 picograms of dioxin [in our samples], public ...
... Congress, held in Boston earlier this year,// a trio ... were awarded the world transplant community's highest honor: The ... mark outstanding new research that will lead to tomorrow's ... is a special issue dedicated to the World Transplant ...
... resulting from excessive binge-alcohol drinking can be prevented ... (ibandronate), a Loyola University Health System study shows. ... which is detrimental to youngsters and young adults, ... osteoporotic post-menopausal women,” said principal study investigator Dr. ...
... and health facilities has revealed that 14 inmates have died// ... deaths are believed to have resulted from treatment errors and ... reported that the jail infrastructure lacks adequate doctors, nurses and ... medical conditions ranging from hernia to heart disease. ...
... times when most people just don’t move away from ... helps them to fulfill psychological needs. ,University of ... and enquired from 1000 gamers their motivation to keep ... Emotion this month suggest that people enjoy video games ...
Cached Medicine News:Health News:Highlights from World Transplant Congress 2Health News:Highlights from World Transplant Congress 3Health News:Vitamin D or Anti-osteoporosis Drug Reduces Bone Loss from Binge Drinking 2Health News:Why People are Addicted to Video Games? 2
The CGRL is a Wide Angle Contact Glass designed for laser photocoagulation and diagnosis of the retina....
For use with Slitlamps which have a smaller distance between the eye and the reduction prism than the Haag-Streit 900. Designed to work with argon/YAG Lasers....
... capture and management system that acquires extremely ... Angiography images. It interfaces with most current ... from any ophthalmic device with video, digital ... quality colour Retinal Images from non-mydriatic fundus ...
... that replaces the old technology, the automated ... bringing virtually unlimited charts to the patient ... at the practitioners finger tips. The STIMULi ... optotypes, associated vision tests and fixation devices ...
Medicine Products: